Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07568652
PHASE1

Clinical Trial to Evaluate the Pharmacokinetics and Safety Between the Single Administration of HL1113 and the Concomitant Administration of HL1113R1 and HL1113R2 for Healthy Subjects in Fasting State

Sponsor: Hanlim Pharm. Co., Ltd.

View on ClinicalTrials.gov

Summary

This clinical trial is a randomized, open-label, single oral dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the single administration of HL1113 and the concomitant administration of HL1113R1 and HL1113R2 for healthy subjects in fasting state

Official title: A Randomized, Open-label, Single Oral Dose, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Single Administration of HL1113 and the Concomitant Administration of HL1113R1 and HL1113R2 for Healthy Subjects in Fasting State

Key Details

Gender

All

Age Range

19 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

37

Start Date

2024-10-16

Completion Date

2024-11-15

Last Updated

2026-05-06

Healthy Volunteers

Yes

Interventions

DRUG

Test group 1

* Period 1 : HL1113R1 + HL1113R2, once daily * Period 2 : HL1113, once daily

DRUG

Test group 2

* Period 1 : HL1113, once daily * Period 2 : HL1113R1 + HL1113R2, once daily

Locations (1)

Central Hospital

Seoul, South Korea